EUVIMEDEUVIMED entdecken
Crossref

Hederagenol improves multiple sclerosis by modulating Th17 cell differentiation

Dongsheng Guan, Yingxia Li, Xu Zhao, Kun Wang, Yanke Guo, Ning Dong, Yinglin Cui iD, Yinghe Gao, Mengmeng Wang, Jing Wang, Yihan Ren, Penghui Shang und 1 weitere

IUBMB Life · 2024

DOI: 10.1002/iub.2863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2024. Verfasst von Dongsheng Guan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, the Second Clinical Medical College, Henan University of Traditional Chinese Medicine, Zhengzhou, China. Hauptthemen laut MEDLINE: Th17 Cells, Encephalomyelitis, Autoimmune, Experimental, Cell Differentiation, Multiple Sclerosis. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Training Fund for Young and middle-aged academic Leaders of Henan Provincial Health Commission, First batch of Chinese medicine top-notch talents training fund of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a common autoimmune illness that is difficult to treat. The upregulation of Th17 cells is critical in the pathological process of MS. Hederagenol (Hed) has been shown to lower IL‐17 levels, although its role in MS pathophysiology is uncertain. In this study, we explore whether Hed could ameliorate MS by modulating Th17 cell differentiation, with the goal of identifying new treatment targets for MS. The experimental autoimmune encephalomyelitis (EAE) mouse model was conducted and Hed was intraperitoneally injected into mice. The weight was recorded and the clinical symptom grade was assessed. Hematoxylin‐eosin staining was carried out to determine the extent of inflammation in the spinal cord and liver. The luxol Fast Blue staining was performed to detect the pathological changes in the myelin sheath. Nerve damage was detected using NeuN immunofluorescence staining and terminal deoxynucleotidyl transferase dUTP nick‐end labeling staining. Immunohistology approaches were used to study alterations in immune cells in the spinal cord. The proportions of T cell subsets in the spleens were analyzed by flow cytometry. RORγt levels were measured using quantitative real‐time PCR or Western blot. The activity of the RORγt promoter was analyzed by Chromatin immunoprecipitation. Hed administration reduced the clinical symptom grade of EAE mice, as well as the inflammatory infiltration, demyelination, and cell disorder of the spinal cord, while having no discernible effect on the mouse weight. In addition, Hed treatment significantly reduced the number of T cells, particularly Th17 cells in the spinal cord and spleen‐isolated CD4 + T cells. Hed lowered the RORγt levels in spleens and CD4 + T cells and overexpression of RORγt reversed the inhibitory effect of Hed on Th17 differentiation. Hed decreased nerve injury by modulating Th17 differentiation through the RORγt promoter. Hed regulates Th17 differentiation by reducing RORγt promoter activity, which reduces nerve injury and alleviates EAE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Th17 CellsEncephalomyelitis, Autoimmune, ExperimentalCell DifferentiationMultiple SclerosisNuclear Receptor Subfamily 1, Group F, Member 3AnimalsMiceFemaleOleanolic AcidMice, Inbred C57BLSpinal CordInterleukin-17

Stichwörter der Autor:innen

EAEHederagenolTh17 differentiationmultiple sclerosis

Substanzen

Nuclear Receptor Subfamily 1, Group F, Member 3Oleanolic AcidRorc protein, mouseInterleukin-17

Autor:innen und Institutionen

  • Department of Neurology, the Second Clinical Medical College, Henan University of Traditional Chinese Medicine, Zhengzhou, China.
  • The College of Basic Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, China.
  • Department of Pharmacy, the Second Clinical Medical College, Henan University of Traditional Chinese Medicine, Zhengzhou, China.

ORCID-Profile: Yinglin Cui

Förderung

  • Training Fund for Young and middle-aged academic Leaders of Henan Provincial Health Commission
  • First batch of Chinese medicine top-notch talents training fund of Henan Province

Zitieren

APA

Guan, D., Li, Y., Zhao, X., Wang, K., Guo, Y., Dong, N., Cui, Y., Gao, Y., Wang, M., Wang, J., Ren, Y., Shang, P., & Liu, Y. (2024). Hederagenol improves multiple sclerosis by modulating Th17 cell differentiation. IUBMB Life. https://doi.org/10.1002/iub.2863

Vancouver

Guan D, Li Y, Zhao X, Wang K, Guo Y, Dong N, et al. Hederagenol improves multiple sclerosis by modulating Th17 cell differentiation. IUBMB Life. 2024. doi:10.1002/iub.2863

BibTeX
@article{Guan2024,
  author = {Guan, Dongsheng and Li, Yingxia and Zhao, Xu and Wang, Kun and Guo, Yanke and Dong, Ning and Cui, Yinglin and Gao, Yinghe and Wang, Mengmeng and Wang, Jing and Ren, Yihan and Shang, Penghui and Liu, Yuxuan},
  title = {Hederagenol improves multiple sclerosis by modulating Th17 cell differentiation},
  journal = {IUBMB Life},
  year = {2024},
  doi = {10.1002/iub.2863}
}
Kostenlos starten →